Afamelanotide
Back to searchScientific Name: | Afamelanotide |
Brand Name: | Scenesse |
Company Owner: | Not Available |
Mechanism Of Action | Patients with erythropoietic porphyria (EPP) have a deficiency of ferrochelatase (FECH) , an enzyme involved in the final step of heme biosynthesis. FECH is required to insert iron into protoporphyrin IX (PPIX) to generate heme, and a deficiency in FECH results in accumulation of PPIX (particularly in the liver and superficial skin vasculature) . PPIX molecules are photodynamic – exposure to UV radiation causes these molecules to form reactive oxygen species that lead to subsequent tissue damage. |
Description of the Drug: | Afamelanotide is an injectable subcutaneous implant used to mitigate phototoxicity secondary to erythropoietic protoporphyria (EPP) . |
Protein Data Bank: | Not Available |
Source: DrugBank Online – DrugBank.com. Retrieved 2023-01-23 from https://go.drugbank.com/drugs/DB04931